Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($1.18), $0.24 better than the analyst estimate of ($1.42). Revenue for the quarter came in at $2.96 million versus the consensus estimate of $2.02 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.